HB 710 (see similar bill HB 243) – Louisiana
Introduced: 2018 Status: Inactive / Dead
PROHIBITS A MANUFACTURER OR WHOLESALE DISTRIBUTOR FROM ENGAGING IN UNRESTRAINED PRICE INCREASES IN THE SALE OF AN ESSENTIAL OFF-PATENT OR GENERIC DRUG: authorizes the secretary of the La. Dept. Of Health to notify the attorney …
HB 7174 – Connecticut
Introduced: 2019 Status: Inactive / Dead
To: (1) Establish the “Connecticut Prescription Drug Program” and the “Connecticut prescription drug program account”; (2) require pharmaceutical manufacturers to send notice to the Insurance Commissioner regarding “pay-for-delay” agreements, and require health carriers and pharmacy …
HB 84 – Alabama
Introduced: 2019 Status: Inactive / Dead
Relating to prescriptions; to amend Section 34-23-8, Code of Alabama 1975, to provide that an electronic prescription from a practitioner specify whether a generic product may be dispensed.
HB 976 (see companion bill SB 2365) – Mississippi
Introduced: 2019 Status: Inactive / Dead
An Act To Amend Section 73-21-73, Mississippi Code Of 1972, To Define The Terms “biological Product” And “interchangeable Biological Product” And Revise The Definition Of The Term “product Selection” For The Purposes Of The Pharmacy …
HF 1183 (see companion bill SF 1265) – Minnesota
Introduced: 2021 Status: Inactive / Dead
Excessive drug price increases prohibited by manufacturers to generic or off-patent drugs, attorney general authorized to take action against manufacturers for price increases, withdrawal of generic or off-patent drug sales prohibited, and civil penalties imposed.
HF 1516 (see companion bill SF 990) – Minnesota
Introduced: 2021 Status: Inactive / Dead
Pharmacy and provider choice allowed relating to biological product prescription and dispensation, and report required. (a) A pharmacy benefit manager or health carrier must not require or demonstrate a preference for a pharmacy or health …
HF 17 (see companion bill SF 168) – Minnesota
Introduced: 2023 Status: In Process
This bill prohibits a manufacturer from imposing or causing to be imposed an excessive price increase on the sale of any generic or off-patent drug. The bill requires the commissioner of health to notify the …
HF 1904 (see companion bill SF 346) – Minnesota
Introduced: 2021 Status: Inactive / Dead
Drug formulary and prior authorization provisions modified, preferred drug list requirements modified, and Formulary Committee reorganizing report required.
HF 204 (see companion bill SF 292) – Iowa
Introduced: 2019 Status: Inactive / Dead
A bill for an act relating to continuity of care and nonmedical switching by health carriers, health benefit plans, and utilization review organizations, and including applicability provisions.
HF 3131 (see companion bill SF 2841) – Minnesota
Introduced: 2018 Status: Inactive / Dead
DRUG MANUFACTURER OR WHOLESALE DISTRIBUTOR PROHIBITED FROM PRICE GOUGING: A manufacturer or wholesale drug distributor may not engage in price gouging in the sale of an essential off-patent or generic drug. A price increase is considered …
HF 4266 (see companion bill SF 3768) – Minnesota
Introduced: 2022 Status: Inactive / Dead
Requiring prescription drug benefit transparency and disclsoure. A health plan company that provides prescription drug benefit coverage and uses a formulary must make its formulary and related benefit information available by electronic means and, upon …
Idaho Code Ann. § 54-1769. Communication regarding biological products: Idaho Pharmacy Act – Idaho
Status: Enacted Year Enacted: 2016
A pharmacist who dispenses a biological product shall communicate to the prescriber the name and manufacturer of the drug within five business days following the dispensing of the biological product. Communication shall occur via an …
Download
Ind. Code §§ 12-17.6-4-1 through 12-17.6-4-8: Children’s Health Insurance Program — Benefits, Crowd Out, and Cost Sharing – Indiana
Status: Enacted Year Enacted: 1999
Statutes provide the benefit package of the children’s health insurance program and which services may require prior authorization. Statutes also outline premium and cost sharing requirements. The office shall require the use of generic drugs …
Download
Iowa Code § 155A.28. Label of prescription drugs — interchangeable biological product list: Iowa Pharmacy Practice Act – Iowa
Status: Enacted Year Enacted: 1987
The board shall maintain a link on its internet site to the current list of all biological products that the United States food and drug administration has determined to be interchangeable biological products.
Download
Iowa Code § 155A.3. Definitions: Iowa Pharmacy Practice Act – Iowa
Status: Enacted Year Enacted: 1987
If an authorized prescriber prescribes a biological product, the pharmacist may exercise professional judgment in the economic interest of the patient by selecting a biological product that is an interchangeable biological product for the biological …
Download
Iowa Code § 514C.19. Prescription contraceptive coverage: Special Health and Accident Insurance Coverages – Iowa
Status: Enacted Year Enacted: 2000
A group policy or contract providing for third-party payment or prepayment of health or medical expenses shall not exclude or restrict benefits for prescription contraceptive drugs or prescription contraceptive devices which prevent conception, or generic …
Download